Myelofibrosis – Medneed

Anemia Drug Myelofibrosis Newly Approved

Ojjaara to treat myelofibrosis in adults with anemia

Drug Name: Ojjaara Active Ingredient: momelotinib Indications: To treat intermediate or high-risk myelofibrosis in adults with anemia Approval Date: 9/15/2023 Company: GlaxoSmithKline More: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216873s000lbl.pdf

Drug Low Platelets Myelofibrosis Newly Approved

Vonjo to treat high-risk myelofibrosis

Drug Name: Vonjo Indications: To treat intermediate or high-risk primary or secondary myelofibrosis in adults with low platelets. Active Ingredient: Company: CTI BioPharma Corp. Approval Date: 2/28/2022 Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208712s000lbl.pdf